the endpoint is attained. Only controlled reports with virologi
(n = 3) or protocol-described composite-endpoints (n = eleven). In buy to expose variances involving virological efficacy and ancillary advantages (e.g. reduced toxicity, far more practical formulation), we extracted modified…